406 completed, 97 terminated, 82 recruiting, 45 active not recruiting. 344 Phase 2, 282 Phase 1, 55 Phase 3, 46 Not applicable, 4 Early Phase 1.
Follow Myelodysplastic-Myeloproliferative Diseases: new trials by email Literature Review of Myelodysplastic-Myeloproliferative Diseases trials Research Report on Myelodysplastic-Myeloproliferative Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phenotypic and Functional Characterization of Bone Marrow Macrophages in Chronic Myelomonocytic Leukemia Bone marrow and blood samples, Bone marrow sample - Chronic Myelomonocytic Leukemia | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 120 | 2026-11-01 | 2026-10-01 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-10-27 | 2026-10-22 |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 35 | 2026-09-29 | 2026-05-06 |
| A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies S241656, Posaconazole - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 64 | 2026-09-15 | 2026-07-22 |
| TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT Tacrolimus, Early Tacrolimus Taper Strategy - GVHD, Hematopoietic Cell Transplantation (HCT) | Phase 1 | Recruiting | Stanford University | 50 | 2026-07-21 | 2026-08-17 |
| Therapeutic RSK1 Targeting in Myeloid Malignancies PMD-026 - Myeloid Malignancy | Phase 1 | Recruiting | Washington University School of Medicine | 30 | 2026-05-20 | 2026-10-21 |
| Cohort of Patients With Chronic Myelomonocytic Leukemia Sampling - Leukemia, Myelomonocytic Leukemia, Chronic | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 5000 | 2026-05-05 | 2026-05-19 | |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| Clonal Hematopoiesis of Immunological Significance observational cohort study - Immune System Diseases, Autoimmune Diseases | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 5000 | 2026-04-01 | 2026-03-23 | |
| Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS CD33 FPBMC - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Recruiting | University of Virginia | 23 | 2026-03-26 | 2026-05-11 |
| Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo) - Vascular Inflammation, ASCVD | Phase 2 | Recruiting | Massachusetts General Hospital | 120 | 2026-03-24 | 2026-10-15 |
| Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia Momelotinib, Azacitidine - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 18 | 2026-03-19 | 2026-03-27 |
| Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia TBF regimen - Chronic Myelomonocytic Leukemia (CMML) | Not applicable | Recruiting | Peking University People's Hospital | 31 | 2026-02-13 | 2026-09-15 |
| Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan - Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-02-04 | 2026-10-19 |
| Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation - Leukemia, Myelodysplasia | Phase 2 | Recruiting | Hannah Choe, MD | 124 | 2026-01-14 | 2026-09-02 |
| Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) Axatilimab (SNDX-6352), Ruxolitinib - Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML) | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 66 | 2026-01-02 | 2026-10-09 |
| Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia Pacritinib, Hydroxyurea - Leukemia, Myelomonocytic, Chronic | Phase 2 | Recruiting | Theradex | 66 | 2026-01-01 | 2026-08-18 |
| Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations Screening - Clonal Mast Cell Disease, KIT D816V Mutation | Recruiting | Blueprint Medicines Corporation | 750 | 2025-10-17 | 2026-10-07 | |
| Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2025-09-26 | 2026-07-20 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
Showing 20 of 692. Sign in to see all of them.
Leukemia, Myelomonocytic, Chronic (540) · Myelodysplastic Syndromes (453) · Leukemia, Myeloid, Acute (447) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (307) · Leukemia (288) · Myeloproliferative Disorders (281) · Leukemia, Lymphocytic, Chronic, B-Cell (228) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (209) · Lymphoma, Non-Hodgkin (205) · Hodgkin Disease (198) · Primary Myelofibrosis (196) · Leukemia, Myeloid, Accelerated Phase (194) · Burkitt Lymphoma (192) · Multiple Myeloma (191)
Hemic and Lymphatic Diseases (692) · Bone Marrow Diseases (686) · Neoplasms by Histologic Type (682) · Hematologic Diseases (680) · Leukemia, Myeloid (671) · Pathological Conditions, Signs and Symptoms (639) · Neoplasms (638) · Pathologic Processes (636) · Disease Attributes (634) · Chronic Disease (629) · Leukemia (395) · Immune System Diseases (362) · Immunoproliferative Disorders (351) · Lymphatic Diseases (350)
Cyclophosphamide (115) · fludarabine phosphate (106) · Azacitidine (85) · Peripheral Blood Stem Cell Transplantation (84) · Busulfan (76) · Mycophenolic Acid (70) · Tacrolimus (65) · Cyclosporine (59) · Whole-Body Irradiation (57) · Cytarabine (56) · Filgrastim (55) · Methotrexate (49) · Antilymphocyte Serum (47) · Decitabine (39) · Melphalan (39)
Fred Hutchinson Cancer Center (62) · M.D. Anderson Cancer Center (59) · National Cancer Institute (NCI) (54) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (25) · Memorial Sloan Kettering Cancer Center (23) · Case Comprehensive Cancer Center (18) · City of Hope Medical Center (17) · Roswell Park Cancer Institute (14) · Children's Oncology Group (13) · St. Jude Children's Research Hospital (12) · OHSU Knight Cancer Institute (10) · Alliance for Clinical Trials in Oncology (9) · European Organisation for Research and Treatment of Cancer - EORTC (8) · H. Lee Moffitt Cancer Center and Research Institute (8) · Masonic Cancer Center, University of Minnesota (8)
United States (572) · France (51) · Canada (48) · Germany (48) · Italy (37) · United Kingdom (34) · Spain (32) · Australia (29) · Belgium (23) · South Korea (18) · China (16) · Switzerland (16) · Netherlands (14) · Czechia (13) · Sweden (11)
Brenda Sandmaier (9) · Jorge Cortes, MD (5) · Kyoo H. Lee, MD (5) · Philip L. McCarthy, MD (5) · Asad Bashey, MD, PhD (4) · Brandon Triplett, MD (4) · Francis Giles (4) · Guillermo Garcia-Manero (4) · Guillermo M Bravo (4) · Judith E. Karp, MD (4) · Ann E. Woolfrey, MD (3) · B. Douglas Smith, MD (3) · B. Smith (3)
PMID 32499241, PMID 42013378, PMID 20802024, PMID 21715313, PMID 26577691, PMID 40554414, PMID 12114413, PMID 12171484, PMID 15107815, PMID 15459300, PMID 15570084, PMID 15817673, PMID 16136166, PMID 16158312, PMID 16278404, PMID 16333838, PMID 16484584, PMID 16609072, PMID 16651647, PMID 17146105, PMID 17315155, PMID 17397698, PMID 17562873, PMID 17640728, PMID 17910637, PMID 17959855, PMID 18055864, PMID 18203012, PMID 18245545, PMID 18327587, PMID 18698002, PMID 18769450, PMID 18974373, PMID 18989154, PMID 18997171, PMID 19270260, PMID 19286996, PMID 19291085, PMID 19304957, PMID 19546476, PMID 19557623, PMID 19652201, PMID 19706886, PMID 19786617, PMID 19841031, PMID 20056794, PMID 20124511, PMID 20413658, PMID 20494931, PMID 20496177
P30CA015704 (25), P30CA006973 (22), P30CA043703 (14), P30CA033572 (12), U01CA070095 (9), P01CA015396 (8), P01CA018029 (8), P30CA068485 (8), P01CA078902 (7), P30CA016672 (7), P30CA022453 (6), P30CA072720 (6), U10CA098543 (6), 2018 (5), P01CA044991 (4)